JP2019150058A5 - - Google Patents

Download PDF

Info

Publication number
JP2019150058A5
JP2019150058A5 JP2019098640A JP2019098640A JP2019150058A5 JP 2019150058 A5 JP2019150058 A5 JP 2019150058A5 JP 2019098640 A JP2019098640 A JP 2019098640A JP 2019098640 A JP2019098640 A JP 2019098640A JP 2019150058 A5 JP2019150058 A5 JP 2019150058A5
Authority
JP
Japan
Prior art keywords
vista
isolated
antagonist
vista antagonist
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019098640A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019150058A (ja
JP6938564B2 (ja
Filing date
Publication date
Priority claimed from US14/534,793 external-priority patent/US20150231215A1/en
Priority claimed from JP2016565137A external-priority patent/JP6885728B2/ja
Application filed filed Critical
Publication of JP2019150058A publication Critical patent/JP2019150058A/ja
Publication of JP2019150058A5 publication Critical patent/JP2019150058A5/ja
Application granted granted Critical
Publication of JP6938564B2 publication Critical patent/JP6938564B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019098640A 2014-11-06 2019-05-27 Ｖｉｓｔａアンタゴニスト及び使用の方法 Expired - Fee Related JP6938564B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/534,793 US20150231215A1 (en) 2012-06-22 2014-11-06 VISTA Antagonist and Methods of Use
US14/534,793 2014-11-06
JP2016565137A JP6885728B2 (ja) 2014-11-06 2015-01-23 Ｖｉｓｔａアンタゴニスト及び使用の方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016565137A Division JP6885728B2 (ja) 2014-11-06 2015-01-23 Ｖｉｓｔａアンタゴニスト及び使用の方法

Publications (3)

Publication Number Publication Date
JP2019150058A JP2019150058A (ja) 2019-09-12
JP2019150058A5 true JP2019150058A5 (https=) 2019-10-24
JP6938564B2 JP6938564B2 (ja) 2021-09-22

Family

ID=58203654

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016565137A Expired - Fee Related JP6885728B2 (ja) 2014-11-06 2015-01-23 Ｖｉｓｔａアンタゴニスト及び使用の方法
JP2019098640A Expired - Fee Related JP6938564B2 (ja) 2014-11-06 2019-05-27 Ｖｉｓｔａアンタゴニスト及び使用の方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016565137A Expired - Fee Related JP6885728B2 (ja) 2014-11-06 2015-01-23 Ｖｉｓｔａアンタゴニスト及び使用の方法

Country Status (1)

Country Link
JP (2) JP6885728B2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6885728B2 (ja) * 2014-11-06 2021-06-16 キングス・カレッジ・ロンドン Ｖｉｓｔａアンタゴニスト及び使用の方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX374075B (es) * 2010-03-26 2025-03-05 Dartmouth College Proteina mediadora de celula t regulatoria vista, agentes de enlace de vista y uso de los mismos.
JP6285923B2 (ja) * 2012-06-22 2018-02-28 トラスティーズ・オブ・ダートマス・カレッジ 新規ＶＩＳＴＡ−Ｉｇコンストラクト及び自己免疫、アレルギー性及び炎症性障害の処置のためのＶＩＳＴＡ−Ｉｇの使用
US9381244B2 (en) * 2012-09-07 2016-07-05 King's College London VISTA modulators for diagnosis and treatment of cancer
JP6885728B2 (ja) * 2014-11-06 2021-06-16 キングス・カレッジ・ロンドン Ｖｉｓｔａアンタゴニスト及び使用の方法

Similar Documents

Publication Publication Date Title
JP7133241B2 (ja) Ｉｆｎと抗ｐｄ－ｌ１抗体の融合タンパク質およびその使用
US10800828B2 (en) Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
US11332537B2 (en) Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs
CA3148621A1 (en) Compositions and methods comprising protease-activated therapeutic agents
CN109195665A (zh) 针对ctla4的单域抗体及其衍生蛋白
AU2017325866B2 (en) PD-1 peptide inhibitors
JP2021508449A5 (https=)
US20220048971A1 (en) Human alpha fetoprotein-specific t cell receptors and uses thereof
CN113614109A (zh) 双功能抗pd-1/il-7分子
CN113574067A (zh) 双功能抗PD-1/SIRPα分子
EP4021943A1 (en) Pharmaceutical formulations and dosage regimens for multi-specific binding proteins that bind her2, nkg2d, and cd16 for cancer treatment
JP2016537340A5 (https=)
JP7193628B2 (ja) 低ａｄｃｃ／ｃｄｃ機能性モノクローナル抗体、及びその調製方法と使用
US20210246219A1 (en) Combination therapies comprising cd137/her2 bispecific agents and pd-1 axis inhibitors and uses thereof
US20210253713A1 (en) Antibodies targeting a complex comprising non-classical hla-i and neoantigen and their methods of use
JP2019526528A5 (https=)
JP2022512541A (ja) Ｐｄ－１系キメラタンパク質を含む併用療法
WO2018012895A1 (ko) 면역관문을 극복한 면역세포 및 상기 면역세포를 포함한 약제학적 조성물
WO2016162867A1 (en) Combination therapy of macrophage activating factor and pd-1 signaling inhibitors
JP2019150058A5 (https=)
US20080254030A1 (en) Use of Baff to Treat Th2-Mediated Conditions
JP2024510577A (ja) 処置
WO2016079276A1 (en) Use of an anti-gm-csf antagonist and an anti-ccr2 antagonist in the treatment of an infectious disease
WO2024189628A1 (en) Lag-3 inhibition for enhanced antiviral immune response
WO2016081801A1 (en) Use of an anti-ccr2 antagonist in the treatment of an infectious disease